ALLMedicine™ Anaplastic Thyroid Carcinoma Center
Research & Reviews 338 results
https://doi.org/10.1530/ERC-23-0016
Endocrine-related Cancer; De Stefano MA, Porcelli T et. al.
Mar 7th, 2023 - Anaplastic thyroid cancer (ATC) is a rare thyroid tumor that frequently originates from the dedifferentiation of a well-differentiated papillary or follicular thyroid cancer. Type 2 deiodinase (D2), responsible for the activation of the thyroid ho...
https://clinicaltrials.gov/ct2/show/NCT03181100
Mar 2nd, 2023 - PRIMARY OBJECTIVE: I. To determine if targeted therapy + atezolizumab (cohorts 1-3) will lead to improved overall survival (OS) in patients with anaplastic thyroid carcinoma (ATC). SECONDARY OBJECTIVES: I. To evaluate the safety and efficacy (Resp...
https://doi.org/10.21873/anticanres.16252
Anticancer Research; Nakayama H, Saito N et. al.
Mar 1st, 2023 - The prognosis of anaplastic thyroid carcinoma (ATC) is poor, and there is currently no established treatment to improve its outcome. We previously reported that enhancer of zeste homolog 2 (EZH2) was highly expressed in ATC, and may be a therapeut...
https://doi.org/10.1080/07357907.2023.2183027
Cancer Investigation; Wächter S, Knauff F et. al.
Feb 23rd, 2023 - Anaplastic thyroid carcinoma (ATC) has poor prognosis, high mortality rate and lack of effective therapy. A synergic combination of PD-L1 antibody together with cell death promoting substances like deacetylase inhibitors (DACi) and multi-kinase in...
https://doi.org/10.1016/j.ijrobp.2023.02.004
International Journal of Radiation Oncology, Biology, Phy... Yang X, Zheng L et. al.
Feb 17th, 2023 - Postoperative cancer recurrence and metastasis have always been a huge challenge in cancer therapy. Concurrent cisplatin (CDDP)-based chemoradiotherapy regimen is a standard therapeutic strategy in some cancer treatment after surgical resection. H...
Guidelines 3 results
https://doi.org/10.1507/endocrj.EJ20-0025
Endocrine Journal; Ito Y, Onoda N et. al.
Apr 10th, 2020 - The Japan Associations of Endocrine Surgeons has developed the revised version of the Clinical Practice Guidelines for Thyroid Tumors. This article describes the guidelines translated into English for the 35 clinical questions relevant to the ther...
https://doi.org/10.6004/jnccn.2018.0089
Journal of the National Comprehensive Cancer Network : JN... Haddad RI, Nasr C et. al.
Dec 14th, 2018 - The NCCN Guidelines for Thyroid Carcinoma provide recommendations for the management of different types of thyroid carcinoma, including papillary, follicular, Hürthle cell, medullary, and anaplastic carcinomas. These NCCN Guidelines Insights summa...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4986600
Journal of the National Comprehensive Cancer Network : JN... Haddad RI, Lydiatt WM et. al.
Sep 12th, 2015 - This selection from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Thyroid Carcinoma focuses on anaplastic carcinoma because substantial changes were made to the systemic therapy recommendations for the 2015 update. Dosage...
Clinicaltrials.gov 6 results
https://clinicaltrials.gov/ct2/show/NCT03181100
Mar 2nd, 2023 - PRIMARY OBJECTIVE: I. To determine if targeted therapy + atezolizumab (cohorts 1-3) will lead to improved overall survival (OS) in patients with anaplastic thyroid carcinoma (ATC). SECONDARY OBJECTIVES: I. To evaluate the safety and efficacy (Resp...
https://clinicaltrials.gov/ct2/show/NCT04592484
Feb 8th, 2023 - This is a first-in-human, Phase 1/2 open-label, multicenter, dose escalation, safety, pharmacodynamic, and PK study of CDK-002 in subjects with advanced/metastatic, recurrent, injectable solid tumors, whose disease has progressed despite receiving...
https://clinicaltrials.gov/ct2/show/NCT05659186
Dec 21st, 2022 - Thyroid cancer (TC) is the most common malignant tumor of the endocrine system. It is more common in women and accounts for approximately 4% of all new malignancies in women. TC can be classified according to its pathological type: papillary carci...
https://clinicaltrials.gov/ct2/show/NCT02114658
Aug 3rd, 2017 - The objectives of this study are to evaluate safety, efficacy and pharmacokinetics of sorafenib for the treatment of Japanese patients with anaplastic thyroid carcinoma (ATC) or locally advanced or metastatic medullary thyroid carcinoma (MTC).
https://clinicaltrials.gov/ct2/show/NCT00507429
Jun 9th, 2014 - Anaplastic thyroid carcinoma (ATC) is a high-grade neoplasm, characterized by an aggressive clinical course with brief survival, and refractoriness to currently available local and systemic modalities of treatment. There is no standard therapy for...
News 19 results
https://www.onclive.com/view/tumor-profiling-studies-illuminate-nuances-across-malignancies
Nov 21st, 2022 - Molecular and immune landscapes for solid tumors are constantly evolving as precision medicine techniques become more sensitive and next-generation sequencing methods (NGS) are taken up in clinical practice. Posters presented at the European Soc...
https://www.onclive.com/view/lenvatinib-pembrolizumab-combo-proves-safe-effective-for-metastasized-anaplastic-and-poorly-differentiated-thyroid-carcinoma
Sep 13th, 2022 - The combination of lenvatinib (Lenvima) and pembrolizumab (Keytruda) was found to induce high response rates, including long-lasting remissions, and have acceptable safety in patients with metastasized anaplastic thyroid carcinoma (ATC) and poorly...
https://www.onclive.com/view/running-a-lot-of-discipline-and-a-little-bit-of-jazz-walter-j-curran-jr-is-a-giant-of-cancer-care-in-radiation-oncology
Apr 6th, 2022 - Walter J. Curran Jr, MD, started a new job this year working for an Australia-based oncology services provider, so it’s no surprise that he spent the summer with his mind and his device screens tethered to the other side of the world. Then again,...
https://www.onclive.com/view/molecular-testing-enhances-decisionmaking-process-in-thyroid-cancer-of-indeterminate-malignancy
Jan 3rd, 2022 - Andrew Turk, MD In thyroid cancer, molecular diagnostic tests enable oncologists to evaluate thyroid nodules with atypical, suspicious, or indeterminate fine-needle aspiration (FNA) cytology to determine the best course of treatment based on cyto...
https://www.onclive.com/view/next-generation-braf-inhibitor-cobicistat-elicits-encouraging-activity-in-braf-refractory-solid-tumors
Oct 6th, 2021 - PLX8394, a next-generation BRAF inhibitor, in combination with cobicistat (Tybost) was found to demonstrate encouraging clinical activity with an acceptable safety profile in patients with BRAF-mutated, refractory solid tumors, according to result...